Core Viewpoint - Haohai Biological Science and Technology Co., Ltd. is facing significant challenges as its core business growth engines have stalled, leading to declining performance and governance issues, despite its previous status as a market star in the medical aesthetics sector [1] Financial Performance - The company reported a revenue of 1.899 billion yuan for the first three quarters of 2025, a year-on-year decline of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down 10.63% year-on-year [2] - The medical aesthetics segment, which contributes the largest share of revenue, has shown signs of fatigue, with hyaluronic acid sales dropping to 347 million yuan in the first half of the year, a significant decline of 16.8% [2] - The eye care business, a strategic focus for the company, has been adversely affected by policy changes and market conditions, with revenue from cataract surgery products, including artificial lenses, decreasing by 28.76% year-on-year, amounting to a reduction of approximately 66.68 million yuan [2] Dividend Policy - Despite declining performance, the company has announced a generous cash dividend of 230 million yuan for the 2024 fiscal year, representing a record high of 54.92% of the annual net profit attributable to shareholders [3] Acquisition Strategy - In response to growth challenges, the company is pursuing external acquisitions, but recent deals have raised concerns due to high valuations and lack of protective measures [4][5] - The company announced a plan to acquire a 19.8% stake in Ruijibio for 38.35 million yuan, despite Ruijibio's poor financial performance, which included a net loss of 11.77 million yuan in 2024 [4] - The acquisition lacks any performance guarantees or compensation mechanisms, raising questions about the rationale behind such a high-priced investment in a loss-making company [5] Related Party Transactions - Prior to the acquisition, the company's controlling shareholder was already the second-largest shareholder of Ruijibio, leading to potential conflicts of interest and concerns about the fairness of the transaction [6] - The company recently completed another acquisition of a 20% stake in a subsidiary, which had previously failed to meet profit targets, resulting in a significant shortfall and raising doubts about the commercial viability of the deal [7]